Table 2. Univariate Analysis for RFS in Training Set and Validation Set.
| Characteristic | Training Set (n = 34) | Validation Set (n = 81) | ||||
|---|---|---|---|---|---|---|
|
|
|
|||||
| n | HR (95%CI) | P | n | HR (95%CI) | P | |
| Age,yr | ||||||
| <60 | 14 | 24 | ||||
| ≥60 | 20 | 0.99 (0.31–3.12) | 0.981 | 57 | 1.41 (0.60–3.32) | 0.430 |
| Sex | ||||||
| Male | 14 | 38 | ||||
| Female | 20 | 1.46 (0.44–4.85) | 0.538 | 43 | 0.85 (0.41–1.79) | 0.672 |
| LNs examined | ||||||
| ≥12 | 23 | 57 | ||||
| <12 | 11 | 2.44 (0.79–7.59) | 0.123 | 24 | 1.44 (0.68–3.08) | 0.345 |
| pT4 | ||||||
| No | 28 | 75 | ||||
| Yes | 6 | 0.34 (0.04–2.64) | 0.302 | 6 | 0.99 (0.24–4.19) | 0.994 |
| Lymphovascular invasion | ||||||
| No | 26 | 69 | ||||
| Yes | 8 | 0.69 (0.15–3.14) | 0.627 | 12 | 2.58 (1.09–6.12) | 0.031 |
| Mucin production | ||||||
| No | 29 | 65 | ||||
| Yes | 5 | 0.50 (0.06–3.86) | 0.504 | 16 | 1.40 (0.59–3.29) | 0.446 |
| Differentiation | ||||||
| Well and moderate | 26 | 69 | ||||
| Poor | 8 | 1.14 (0.31–4.20) | 0.848 | 12 | 0.42 (0.10–1.77) | 0.238 |
| Location | ||||||
| Right colon | 15 | 43 | ||||
| Left colon and rectum | 19 | 2.62 (0.71–9.68) | 0.150 | 38 | 0.92 (0.44–1.93) | 0.817 |
| KRAS mutations | ||||||
| No | 19 | 56 | ||||
| Yes | 15 | 1.83 (0.59–5.73) | 0.298 | 25 | 1.11 (0.50–2.45) | 0.802 |
| MSI status | ||||||
| MSS | 19 | 40 | ||||
| MSI | 15 | 0.66 (0.20–2.19) | 0.495 | 41 | 0.71 (0.33–1.49) | 0.705 |
| Group by cutoff 4 | ||||||
| U group | 22 | 42 | ||||
| M group | 12 | 2.02 (0.65–6.26) | 0.226 | 39 | 1.50 (0.71–3.18) | 0.288 |
| Group by cutoff 10 | ||||||
| Low-risk group | 26 | 48 | ||||
| High-risk group | 8 | 4.60 (1.46–14.44) | 0.009 | 33 | 2.21 (1.04–4.68) | 0.039 |
M indicates IGFBP-3 methylated; U, IGFBP-3 unmethylated.